We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.13%
2 Consumer Staples 1.53%
3 Miscellaneous 1.39%
4 Industrials 0.67%
5 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.51B
$194M 4.88%
305,600
+5,800
+2% +$2.99M
HUM icon
2
Humana
HUM
$46.2B
$160M 4.04%
368,600
+19,600
+6% +$8.2M
PODD icon
3
Insulet
PODD
$9.75B
$128M 3.23%
481,700
+17,950
+4% +$4.41M
UNH icon
4
UnitedHealth
UNH
$337B
$122M 3.08%
240,000
– –
IDXX icon
5
Idexx Laboratories
IDXX
$40.5B
$120M 3.01%
218,750
+38,750
+22% +$20.4M
ARGX icon
6
argenx
ARGX
$61.6B
$110M 2.78%
350,000
+35,000
+11% +$10.2M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.2B
$104M 2.61%
1,105,000
– –
ALGN icon
8
Align Technology
ALGN
$10.7B
$94.4M 2.38%
216,500
+16,500
+8% +$8.03M
HCA icon
9
HCA Healthcare
HCA
$93.2B
$94M 2.37%
375,000
-75,000
-17% -$18.8M
ISRG icon
10
Intuitive Surgical
ISRG
$135B
$90.1M 2.27%
298,500
-61,500
-17% -$18M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$78.5M 1.98%
746,000
– –
AGIO icon
12
Agios Pharmaceuticals
AGIO
$1.97B
$77.6M 1.95%
2,665,275
+18,650
+0.7% +$570K
EVH icon
13
Evolent Health
EVH
$423M
$76.9M 1.94%
2,380,000
+342,000
+17% +$8.95M
PCRX icon
14
Pacira BioSciences
PCRX
$993M
$76.3M 1.92%
1,000,000
– –
IMCR icon
15
Immunocore
IMCR
$1.63B
$76.3M 1.92%
2,552,034
+80,479
+3% +$2.03M
RARE icon
16
Ultragenyx Pharmaceutical
RARE
$1.27B
$74.7M 1.88%
1,028,109
+144,188
+16% +$10M
EW icon
17
Edwards Lifesciences
EW
$51.5B
$70.2M 1.77%
596,500
+14,500
+2% +$1.63M
IRTC icon
18
iRhythm Holdings
IRTC
$3.69B
$68.7M 1.73%
436,000
+3,000
+0.7% +$385K
ACRS icon
19
Aclaris Therapeutics
ACRS
$783M
$66.6M 1.68%
3,865,034
+3,687
+0.1% +$50.3K
FRPT icon
20
Freshpet
FRPT
$2.98B
$60.8M 1.53%
592,500
+12,500
+2% +$1.18M
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$60.5M 1.52%
947,715
+87,960
+10% +$6.31M
CERE
22
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$60.3M 1.52%
1,723,341
+74,906
+5% +$2.19M
BAX icon
23
Baxter International
BAX
$12.2B
$58.2M 1.47%
750,700
+16,897
+2% +$1.41M
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$56.3M 1.42%
271,500
+49,000
+22% +$8.08M
KRTX
25
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.8M 1.38%
432,543
+5,700
+1% +$642K
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Miscellaneous.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.